Trials / Completed
CompletedNCT00160212
Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension
A Randomized, Placebo-Controlled, Double-Blind, Six-Arm, Dose Escalation, Multi-Center Study to Evaluate the Efficacy and Safety of SLV306: 150, 300, 600 mg Once Daily, 150-300 mg Twice Daily and Amlodipine 5-10 mg Once Daily in Subjects With Hypertension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to compare the efficacy and safety of increasing doses of SLV306 with amlodipine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Daglutril |
Timeline
- Start date
- 2004-12-01
- First posted
- 2005-09-12
- Last updated
- 2009-01-30
Locations
130 sites across 11 countries: Australia, Bulgaria, Denmark, Estonia, Germany, Hungary, Israel, Latvia, Lithuania, Slovakia, United Kingdom
Source: ClinicalTrials.gov record NCT00160212. Inclusion in this directory is not an endorsement.